

**AHLCON PARENTERALS (INDIA) LIMITED**  
Regd Office: 4, Community Centre, Saket, New Delhi - 110017  
**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2011**

(Rs. In Lacs)

Sl No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2011	30.09.2011	31.12.2010	31.12.2011	31.12.2010	31.03.2011
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Gross Sales/Income from Operations	2,110.90	2,252.98	1,703.55	6,637.35	4,867.53	6,713.01
	Less: Excise Duty	(148.28)	(202.20)	(132.84)	(563.79)	(384.74)	(530.45)
	Net Sales/Income from Operations	1,962.62	2,050.78	1,570.71	6,073.56	4,482.79	6,182.56
b	Other Operating Income	28.36	16.94	20.34	70.18	28.82	50.32
	<b>Total (a+b)</b>	<b>1,990.98</b>	<b>2,067.72</b>	<b>1,591.05</b>	<b>6,143.74</b>	<b>4,511.61</b>	<b>6,232.88</b>
2	Expenditure						
	(Increase) / decrease in stock in trade and work in progress	(36.06)	(43.37)	45.21	(61.89)	(84.66)	(134.23)
	Consumption of raw materials	713.38	867.73	617.26	2,366.86	1,609.65	2,333.74
	Purchase of traded goods			1.52		117.20	118.97
	Power, Fuel & Water	238.90	272.91	175.60	758.41	494.24	676.55
	Employees cost	337.43	318.60	279.67	980.66	746.00	1,044.24
	Depreciation	84.80	83.47	86.29	249.96	208.96	289.32
	Other expenditure	339.84	294.89	251.70	933.19	731.94	1,077.27
	<b>Total</b>	<b>1,679.09</b>	<b>1,814.03</b>	<b>1,457.25</b>	<b>5,227.20</b>	<b>3,823.33</b>	<b>5,405.86</b>
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	311.89	253.69	133.80	916.54	688.28	827.02
4	Other Income	12.41	11.58	2.48	31.59	18.65	46.35
5	Profit before Interest and Exceptional Items (3+4)	324.30	265.27	136.29	948.13	706.92	873.37
6	Interest	81.34	79.88	80.24	244.81	158.06	225.12
7	Profit after interest but before Exceptional Items (5-6)	242.96	185.39	56.05	703.32	548.86	648.25
8	Exceptional Items						
9	Profit (+) / Loss (-) from Ordinary Activities before tax (7+8)	242.96	185.39	56.05	703.32	548.86	648.25
10	Tax expenses	74.82	62.78	50.48	221.66	214.30	219.07
11	Profit (+) / Loss (-) from Ordinary Activities after tax (9-10)	168.14	122.61	5.57	481.76	334.56	429.18
12	Extraordinary Item						
13	Net Profit (+) / Loss (-) for the period (11-12)	168.14	122.61	5.57	481.76	334.56	429.18
14	Paid-up equity share capital (Face Value of the Share : Rs. 10/- each)	720.01	720.01	720.01	720.01	720.01	720.01
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						2,999.98
16	Earnings Per Share (EPS)						
	Basic and diluted EPS before Extraordinary Items for the period (not annualized), and for the previous year.	2.31	1.68	0.06	6.62	4.62	5.87
	Basic and diluted EPS after Extraordinary Items for the period (not annualized), and for the previous year.	2.31	1.68	0.06	6.62	4.62	5.87
17	Public Shareholding						
	- No. of shares	2091945	2091945	2091945	2091945	2091945	2,091,945
	- Percentage of shareholding	29.05%	29.05%	29.05%	29.05%	29.05%	29.05%
18	Promoters and promotor group Shareholding						
	- Number of Shares	5108205	5108205	5108205	5108205	5108205	5,108,205
	- Percentage of shares (as a % of the total share capital of the company)	70.95%	70.95%	70.95%	70.95%	70.95%	70.95%
	Pledged / Encumbered						
	- Number of Shares	0	0	1400000	0	1400000	1,400,000
	- Percentage of shares (as a % of the total shareholding of promoters and promotor group)	0	0	27.41%	0	27.41%	27.41%
	- Percentage of shares (as a % of the total share capital of the company)	0	0	19.444%	0	19.444%	19.44%
	Non Encumbered						
	- Number of Shares	5108205	5108205	3708205	5108205	3708205	3,708,205
	- Percentage of shares (as a % of the total shareholding of promoters and promotor group)	100.00%	100.00%	72.59%	100.00%	72.59%	72.59%
	- Percentage of shares (as a % of the total share capital of the company)	70.95%	70.95%	51.50%	70.95%	51.50%	51.50%

**Notes:**

- Figures have been regrouped / rearranged to make them comparable, wherever considered necessary.
- The activities of the Company relate to single segment i.e. pharmaceuticals business segment and has only one reportable segment. Revenue by geographical segment is shown below :

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2011	30.09.2011	31.12.2010	31.12.2011	31.12.2010	31.03.2011
	(Rs in Lakhs)					
Revenue within India	1,541.03	1,966.71	1,481.25	5,492.07	4,387.93	6,033.20
Revenue outside India	569.87	286.27	222.30	1,145.28	479.60	679.81
<b>Total</b>	<b>2,110.90</b>	<b>2,252.98</b>	<b>1,703.55</b>	<b>6,637.35</b>	<b>4,867.53</b>	<b>6,713.01</b>

- The Board of Directors at their meeting held today have declared an Interim Dividend of Rupee 1.00 per equity share (10%) of Rs 10/- each for the financial year 2011-12. The record date for the same has been fixed on Tuesday the 21st February 2012.
- Information on investor complaints for the quarter in numbers: Opening- 0, Received -28, Disposed Off -28, and Closing -0.
- The statutory auditors of the company have carried out a limited review of the results for the quarter ended on 31.12.2011.
- The above results have been reviewed by the Audit Committee on 08.02.2012, approved and taken on record by the Board at its meeting held on 13.02.2012.

Place: New Delhi  
Date: 13.02.2012



For and on behalf of the Board  
*[Signature]*  
Chairman

**LIMITED REVIEW REPORT**

To,  
The Board of Directors,  
Ahlcon Parenterals (India) Limited,  
4, Community Centre, Saket,  
New Delhi-110017


Dear Sirs,


We have reviewed the accompanying statement of unaudited financial results of Ahlcon Parenterals (India) Limited for the period ended 31<sup>st</sup> December, 2011 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Arun K. Gupta & Associates  
Chartered Accountants  
Firm Registration No. 001602N

  
(Sachin Kumar)  
Partner  
M.No. 503204



Place : New Delhi  
Date : 13.02.2012